Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice
- 15 December 2016
- journal article
- Published by American Society of Hematology in Blood
- Vol. 128 (24), 2774-2784
- https://doi.org/10.1182/blood-2015-11-683490
Abstract
Key Points The widely used diabetes drug metformin improves hematopoiesis and delays tumor formation in a preclinical murine model of FA. Metformin reduces DNA damage in human FA patient–derived cells.Keywords
This publication has 56 references indexed in Scilit:
- Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathwayGenes & Development, 2012
- Gene Therapy for Fanconi Anemia: One Step Closer to the ClinicHuman Gene Therapy, 2012
- Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP PhosphodiesterasesCell, 2012
- Cellular and molecular mechanisms of metformin: an overviewClinical Science, 2011
- Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cellsNature, 2010
- Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metforminPharmacogenetics and Genomics, 2010
- Hematopoietic Stem Cell Defects in Mice with Deficiency of Fancd2 or Usp1The International Journal of Cell Cloning, 2010
- Kinetic and Cellular Characterization of Novel Inhibitors of S-Nitrosoglutathione ReductasePublished by Elsevier BV ,2009
- Fanconi anemia and its diagnosisMutation Research, 2009
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003